it would seem prudent that the safeguards we have adopted twice, by unanimous votes, should also be applied to this proposal. That is why I offer this amendment. We should be certain that any change we make results in no less protection in terms of the safety of the drugs supplied to the American people and will indeed make prescription drugs more affordable. Liberalization of protections that are designed to keep unsafe drugs out of this country, especially considering the terrorist threats we face now, should occur only if the necessary safeguards are in place. This amendment will ensure that the concerns of the last two administrations regarding the safety and cost-effectiveness are addressed prior to the implementation of this proposal. Currently, under the Federal Food, Drug, and Cosmetic Act, it is unlawful for anyone to introduce into interstate commerce a new drug that is not covered by an approved new drug application or an abbreviated new drug application. Approval must be sought on a manufacturer and product-by-product basis. A product that does not comply with an approved application, including an imported drug not approved by FDA for marketing in the United States, may not be imported, even if approved for sale by that country.
On the recordJune 19, 2003
Source
govinfo.govEditor's note · Context
Discussing the importance of drug safety and protections during a legislative amendment proposal.
Share
More from Thad Cochran
Jun 21, 2017
Mr. Chairman, let me join you in congratulating our panel here and the participation you're bringing to this challenge.
Mar 28, 2017
This Committee has consistently recommended funding for increased medical research.
Dec 5, 2017
I am pleased to commend Bonnie Kind, who has dedicated her professional career to serving the American people since starting her career with the Social Security Administration, SSA, as a student trainee more than 40 years ago. Bonnie…
Apr 5, 2017
The Sleep Research Society is pleased to submit this statement for the record asking you to provide $250 billion for the Department of Defense (DOD) Peer Reviewed Medical Research Program.





